{"created":"2023-06-19T10:43:59.082651+00:00","id":4344,"links":{},"metadata":{"_buckets":{"deposit":"62f11caf-457d-4a99-bf38-cea0754841a1"},"_deposit":{"created_by":11,"id":"4344","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"4344"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00004344","sets":["30:38:39","77:78:79"]},"author_link":["8611","3129","675","9169","8708","674","2600"],"item_4_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022-09-07","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"5","bibliographicPageEnd":"2472","bibliographicPageStart":"2465","bibliographicVolumeNumber":"36","bibliographic_titles":[{},{"bibliographic_title":"In Vivo","bibliographic_titleLang":"en"}]}]},"item_4_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"小出, 博義"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"野田, 哲史"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"奥貫, 裕美"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"大脇, 成広"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"清水, 猛史"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"森田, 真也"}],"nameIdentifiers":[{},{},{}]}]},"item_4_description_14":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"pdf","subitem_description_type":"Other"}]},"item_4_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background/Aim:\nConcurrent chemoradiotherapy with high-dose cisplatin (CDDP-RT) is the standard therapy for advanced head and neck cancer; however, due to CDDP-induced renal impairment, dose reduction or discontinuation is frequently required. Therefore, the identification of risk factors for renal impairment is of importance to improve the efficacy and safety of CDDP-RT. ","subitem_description_type":"Abstract"},{"subitem_description":"Patients and Methods: \nWe retrospectively investigated risk factors for renal impairment in advanced head and neck cancer patients receiving CDDP-RT. Renal impairment was defined as a >25% decrease from baseline in estimated glomerular filtration rate within 14 days after CDDP administration in the first cycle. ","subitem_description_type":"Abstract"},{"subitem_description":"Results:\nOf the 82 patients analyzed in this study, 21 (26%) patients developed renal impairment. Multivariate logistic regression analysis showed that concomitant use of a calcium channel blocker or lower hemoglobin levels significantly contributed to the increased risk of CDDP-induced renal impairment (odds ratio=3.60, 95% confidence interval=1.04-12.40; odds ratio=0.71, 95% confidence interval=0.50-0.99, respectively), while concomitant use of proton pump inhibitors was a factor associated with a decreased risk of CDDP-induced renal impairment (odds ratio=0.20, 95% confidence interval=0.04-0.86). ","subitem_description_type":"Abstract"},{"subitem_description":"Conclusion:\nRenal function of patients receiving calcium channel blocker or patients with lower hemoglobin levels should be monitored cautiously when receiving CDDP-RT. ","subitem_description_type":"Abstract"}]},"item_4_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Journal Article","subitem_description_type":"Other"}]},"item_4_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"International Institute of Anticancer Research"}]},"item_4_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"36099135","subitem_relation_type_select":"PMID"}}]},"item_4_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.21873/invivo.12982"}],"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.21873/invivo.12982","subitem_relation_type_select":"DOI"}}]},"item_4_relation_13":{"attribute_name":"PMCID","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"PMC9463891"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9463891/","subitem_relation_type_select":"URI"}}]},"item_4_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. "}]},"item_4_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1791-7549","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"KOIDE, Hiroyoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"NODA, Satoshi"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"OKUNUKI, Yumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"OWAKI, Shigehiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"SHIMIZU, Takeshi"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"TERADA, Tomohiro"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"MORITA, Shin-ya"}],"nameIdentifiers":[{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-10-13"}],"displaytype":"detail","filename":"invivo.12982.pdf","filesize":[{"value":"562.4 kB"}],"format":"application/pdf","license_note":"This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license\n (https://creativecommons.org/licenses/by-nc-nd/4.0).","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"invivo.12982","url":"https://shiga-med.repo.nii.ac.jp/record/4344/files/invivo.12982.pdf"},"version_id":"954312a5-b027-4f88-b5d4-556ced5f18b8"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"cisplatin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"chemoradiotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"renal impairment","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"head and neck cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Analysis of Risk Factors for High-dose Cisplatin-induced Renal Impairment in Head and Neck Cancer Patients","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Analysis of Risk Factors for High-dose Cisplatin-induced Renal Impairment in Head and Neck Cancer Patients"}]},"item_type_id":"4","owner":"11","path":["39","79"],"pubdate":{"attribute_name":"公開日","attribute_value":"2022-10-13"},"publish_date":"2022-10-13","publish_status":"0","recid":"4344","relation_version_is_last":true,"title":["Analysis of Risk Factors for High-dose Cisplatin-induced Renal Impairment in Head and Neck Cancer Patients"],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-06-19T11:10:54.508246+00:00"}